blood banks | Facts You May Not Know About Storing Cord Blood
http://www.cordbloodrecommendation.com These findings bring new hope to those who suffer from acute kidney failure, a life threatening condition. One of the studies was carried out by the Wake Forest University which is located in Winston-Salem, N. Lastly, what is their pricing structure like? Trust me, I know that this isn #39;t the time to go bargain hunting, but neither is it the time to be the victim of price-gouging. These trained and knowledgeable individuals will be able to answer any and all questions regarding cord blood storage and the fees and tasks associated with the storage. There is much controversy regarding the use of stem cell research as it pertains to the use of embryos. Extracting bone marrow is a very painful and difficult procedure, and if you have your own blood, then you do not need to make your family members go through the bone marrow transplant procedure. In order to keep it sterilized, it is then cryogenically stored either in a public or private bank until it is needed for transplant. Preserved stem cells are used when the body is in a weakened state from disease or treatments such as chemotherapy. Cord blood stem cell therapy has regenerative characteristics. Stem cell transplants can save lives of people with serious diseases, such as leukemia (cancer of the white blood cells) and other cancers, or those with serious blood disorders (aplastic anemia). There are currently studies which are researching the possibility of using stem cells to treat ...From:loshoteles enmedellinViews:0 0ratingsTime:01:18More inScience Technology

The rest is here:
blood banks | Facts You May Not Know About Storing Cord Blood - Video

stem cell therapy @ kapuso jessica soho
LAMININE It #39;s not often that the perfect super-supplement with the perfect story comes around, but the story of Laminine is far from a mythical tale. As far back as 1929, a Medical Doctor in Canada discovered a way to extract the #39;life-essence #39; of a nine day old fertilized avian egg. Through research, it was found that on exactly the ninth day, all the ingredients necessary to create life are at its #39; highest level. In fact, the life-giving proteins are so potent at this stage that a live chick is hatched a mere two weeks thereafter. This method of extraction and freeze-drying processes proved to be a historical monumental success for this Medical Doctor #39;s patients. 09333737867 for infoFrom:xpalfredViews:1 1ratingsTime:12:00More inHowto Style

See the article here:
stem cell therapy @ kapuso jessica soho - Video

JERUSALEM--(BUSINESS WIRE)--

Gamida Cell Ltd., a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, announced today that the first patient, enrolled in its pilot study of NiCord as an investigational treatment for sickle cell disease (SCD), has been transplanted at Duke University in North Carolina.

Gamida Cell CEO Dr. Yael Margolin said, The NiCord study is a first step in broadening Gamida Cells pipeline of cell therapies to treat patients who suffer from severe non-malignant diseases with a very large unmet clinical need.

SCD is a group of inherited red blood cell disorders where red blood cells become hard and sticky and look like a C-shaped farm tool called a sickle. According to statistics, SCD affects 90,000 to 100,000 in the US alone, mainly African-Americans and Hispanic-Americans. Symptoms range in type and severity. SCD can be fatal and to date, the only cure for SCD is stem cell transplantation from a family related matched donor.

Dr. Margolin continued, Sickle cell disease can be cured with a successful bone marrow transplantation, especially from a family related fully matched donor. Most patients do not pursue this option, since they do not have the suitable donor. NiCord is intended to reverse this situation and provide a readily available cure.

NiCord is an expanded cell graft derived from an entire unit of umbilical cord blood and enriched with stem cells. NiCord was developed based on Gamida Cells proprietary NAM technology.

The official name of the study is Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Sickle Cell Disease. http://www.clinicaltrials.gov/ct2/show/NCT01590628?term=nicord&rank=1. A total of 10 patients, ages 2 21, will be enrolled in the NiCord study, a single center, single arm trial evaluating the safety and efficacy of transplanting NiCord together with a second un-manipulated cord blood unit in patients with SCD following myeloablative therapy. The study will also assess transplant-related mortality, event-free survival and overall survival at 100, 180 and 365 days, respectively.

About Gamida Cell

Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The companys pipeline of stem cell therapy products are in development to treat a wide range of conditions including blood cancers, solid tumors, non-malignant hematological diseases such as hemoglobinopathies, neutropenia and acute radiation syndrome, autoimmune diseases and metabolic diseases as well as conditions that can be helped by regenerative medicine. Gamida Cells therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood, bone marrow and peripheral blood, which are expanded in culture. Gamida Cells current shareholders include: Elbit Imaging (EMITF), Clal Biotechnology Industries (CBI.TA), Israel Healthcare Venture, Teva Pharmaceutical Industries (TEVA), Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: http://www.gamida-cell.com.

Read the original:
First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at ...

Progenitor Cell Therapy For Neurological Injury
ll4.me Progenitor Cell Therapy For Neurological Injury Preface.- Chapter 1. Basics of Stem and Progenitor Cells.- Chapter 2. Progenitor Cell Tissue Engineering: Scaffold Design and Fabrication.- Chapter 3. Stem Cell Delivery Methods and Routes.- Chapter 4. Neural Stem Cells-Endogenous Repair of Neurological Injury.- Chapter 5. Traumatic Brain Injury: Pathophysiology and Models.- Chapter 6. Traumatic Brain Injury: Relationship of Clinical Injury to Progenitor Cell Therapeutics.- Chapter 7. Cell-Based Therapy for Stroke.- Chapter 8. Spinal Cord Injury: Pathophysiology and Progenitor Cell Therapy.- Chapter 9. Current Status of Clinical Trials using Progenitor Cells for Neurological Injury EAN/ISBN : 9781607619659 Publisher(s): Springer, Berlin, Springer Science Business Media Discussed keywords: Neurologie, Zelltherapie Format: ePub/PDF Author(s): Cox, Charles S. Preface.- Chapter 1. Basics of Stem and Progenitor Cells.- Chapter 2. Progenitor Cell Tissue Engineering: Scaffold Design and Fabrication.- Chapter 3. Stem Cell Delivery Methods and Routes.- Chapter 4From:dorethacopeland98549Views:0 0ratingsTime:00:14More inPeople Blogs

View post:
Progenitor Cell Therapy For Neurological Injury - Video

Charles - USA Stem Cells Testimonial
If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.From:USAStemcellsViews:4 0ratingsTime:10:04More inScience Technology

Originally posted here:
Charles - USA Stem Cells Testimonial - Video

SHIMMIAN MANILA - Celebs share good effects of stem cell therapy
From:myrenovatiosolutionsViews:1 0ratingsTime:01:30More inEntertainment

See the original post:
SHIMMIAN MANILA - Celebs share good effects of stem cell therapy - Video

I'm pleased to point out that today the LinkedIn Cell Therapy Industry Group welcomed its 4,000th member today. 


The Cell Therapy Industry group was created to serve as a network of those in the cell therapy industry. The group acts as a vehicle for referrals, networking, information, and facilitating collaboration.  The group's focus is on the activities of companies in and serving the space.


The group began in July 2008. It took 2.5 years to reach the first 1000 members, 9 mos to reach 2,0000, 6 months to reach 3,000, and 6 months to meet today's 4,000 member mark. 


As is typical, there is a very high percentage of passive participants but the group benefits from an avid group of participants who post, share, exchange, and debate on a range of topics ranging from regulatory, clinical, commercial, scientific, manufacturing, financial, and other topics of interest to the group.


As the group has grown I've noted two trends pertaining to the composition of the membership:  (a) having tapped out the c-level suite, growth is increasingly coming from down the hierarchy of the corporate food chain and including those in the operational trenches, and (b) a much higher ratio of new members of late is from outside the US, presumably as LinkedIn increasingly penetrates OUS markets.


We strive hard to maintain the quality of the participation by screening each applicant, deleting off-topic posts, moving promotional posts to the "promotions" tab" and encouraging a balance of news-sharing with useful discussion threads.


I'm proud to say the group has become a vibrant and valuable part of the sector due to the hard work and contributions of all involved.    


As these kind of virtual networks become exponentially larger and provide different value than the professional societies representing the sector, I will be fascinated to watch if and how this affects how sectors like our interact and how this will impact the traditional value proposition of member-based professional societies.


If you are not a member of the LinkedIn Cell Therapy Industry Group, check it out.


--Lee

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/EOlUEgJGsTQ/cell-therapy-industry-group-welcomes.html

R. Bolli - Interim Results of the SCIPIO Trial Up to 2 Years After Therapy
R. Bolli - Effect of Cardiac Stem Cells in Patients with Ischemic Cardiomyopathy: Interim Results of the SCIPIO Trial Up to 2 Years After Therapy SCIPIO: (Cardiac) Stem Cell Infusion in Patients with Ischemic cardiomyopathy Annual Session of the American Heart Association November 5, 2012, Los AngelesFrom:CardioletterViews:3 0ratingsTime:09:07More inScience Technology

Read the original post:
R. Bolli - Interim Results of the SCIPIO Trial Up to 2 Years After Therapy - Video

By E.J. Mundell HealthDay Reporter

TUESDAY, Nov. 6 (HealthDay News) -- Updated two-year results from a small trial using cardiac stem cells to repair damaged hearts suggest the treatment's healing effect persists.

Patients with heart failure caused by prior heart attacks who got the treatment continue to see reductions in cardiac scar tissue, improvements in the heart's pumping ability and even a boost in their quality of life, researchers said.

These improvements seem to be continuing as time goes on, suggesting that stem cell therapy's healing power hasn't diminished.

"Now we need to perform larger and randomized, blinded studies ... to confirm this data," said study lead author Dr. Roberto Bolli, director of the Institute of Molecular Cardiology at the University of Louisville.

His team presented its results Tuesday at the American Heart Association's annual meeting, in Los Angeles.

According to the AHA, more than 6 million Americans suffer from heart failure, a gradual weakening of the heart often caused by damage from a prior heart attack. Despite its prevalence and lethality, virtually no advance has been made over the past few decades in doctors' ability to treat or reverse heart failure.

That's why the advent of stem cell therapy has encouraged researchers. Stem cells have the ability to turn into myriad living cells, and the hope is that once infused into the heart they can help repair it.

This trial is the first human trial to test this theory using the patient's own cardiac stem cells. The cells used in the trial were harvested from 33 heart failure patients who were undergoing bypass surgery. The cells were then coaxed to multiply into the millions in the lab and then transplanted back into 20 of the patients. The remaining 13 patients did not receive a stem cell infusion and are the "control" group for comparison purposes.

Results gathered one year after treatment showed improvements for the treated patients, but experts questioned whether those gains would fade over time.

See the original post:
Two Years On, Stem Cells Still Healing Damaged Hearts

Study Highlights:

LOS ANGELES, Nov. 6, 2012 (GLOBE NEWSWIRE) -- Cardiac stem cells may one day be an effective treatment for heart failure caused by muscle scarring after a heart attack, according to late-breaking clinical trial results presented at the American Heart Association's Scientific Sessions 2012.

In the Effect of Cardiac Stem Cells In Patients with Ischemic CardiOmyopathy (SCIPIO) trial, heart function and quality of life improved in 20 people treated with their own cardiac stem cells (CSCs).

"This is exciting," said Roberto Bolli, M.D., lead author of the trial, chief of Cardiovascular Medicine and director of the Institute of Molecular Cardiology at the University of Louisville in Kentucky. "The effect of these cells has continued for up to two years, and has gotten stronger. There was also a major reduction in heart scarring."

In 33 patients with heart failure who had undergone coronary artery bypass surgery, researchers removed a tiny piece of heart tissue and isolated heart stem cells called c-kit CSCs. Researchers then grew additional cells to infuse into 20 volunteers assigned to treatment.

Among outcomes found two years after treatment:

"We have not seen any deaths among the patients, or any adverse effects that can be ascribed to the stem cells," Bolli said.

About 6.6 million Americans suffer from heart failure, according to the American Heart Association. Life expectancy is about five years after diagnosis. Ischemic heart attacks cause most of the 57,000 U.S. deaths a year due to heart failure.

Larger, multi-center studies are needed to confirm the findings, Bolli said.

The Jewish Hospital, University of Louisville, and the National Institutes of Health funded the study. Co-authors' names are on the abstract.

Read more here:
Cardiac Stem Cells May Help Treat Heart Failure

Public release date: 7-Nov-2012 [ | E-mail | Share ]

Contact: Deborah Mann Lake deborah.m.lake@uth.tmc.edu 713-500-3030 University of Texas Health Science Center at Houston

HOUSTON (Nov. 7, 2012) Administering stem cells derived from patients' own bone marrow either three or seven days after a heart attack is safe but does not improve heart function six months later, according to a clinical trial supported by the National Institutes of Health (NIH).

The results of the trial, called Transplantation In Myocardial Infarction Evaluation (TIME), mirror a previous related study, LateTIME, which found that such cells (called autologous stem cells) given two to three weeks after a heart attack did not improve heart function. Both TIME and LateTIME were conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute.

The findings were presented Nov. 6, 2012, at the American Heart Association 2012 Scientific Sessions in Los Angeles and appeared concurrently in the Journal of the American Medical Association.

"These cells, while safe, were not better than placebo solution in providing benefit," said Lemuel Moy, III, M.D., Ph.D., principal investigator of the CCTRN and professor of biostatistics at The University of Texas School of Public Health, part of The University of Texas Health Science Center at Houston (UTHealth). "While this one cell type showed little promise, there are several new cell types that are available and we will be studying them. Cell therapy can and likely will play a major role in the treatment of cardiovascular disease in the future."

"This study was extremely valuable even though it did not provide a demonstrated health benefit after six months," said Sonia Skarlatos, Ph.D., deputy director of NHLBI's Division of Cardiovascular Sciences and member of the CCTRN. "Heart stem cell therapy research is still in its infancy, and results from early trials have varied greatly due to differences in the numbers of stem cells injected, the delivery methods used, and the compositions of the study populations. With TIME and LateTIME, we have established both safety and baseline results in two large studies that followed the same procedures for growing and then administering stem cells. This standard will inform the next steps in research on the use of stem cells to repair damaged hearts."

Skarlatos noted that another advantage of the TIME study is that CCTRN is storing samples of the stem cells taken from the participants. Investigators can examine the relationship between people who showed significant improvement during the study and the characteristics of their stem cells. Such a comparison may offer insights on the cell traits that are associated with clinical improvement.

Between July 2008 and February 2011, TIME researchers enrolled 120 volunteers (average age 57, 87.5 percent male) who suffered from moderate to severe impairment in their left ventricles the part of the heart that pumps oxygen-rich blood to the body and had undergone stenting procedures following heart attacks. Those selected for the trial were assigned randomly to one of four groups: day three after heart attack stem cell injection, day three after heart attack placebo injection, day seven after heart attack stem cell treatment, or day seven after heart attack placebo treatment. The researchers developed a method of processing and purifying the stem cells to ensure that participants in the stem cell groups received a uniform dose of 150 million cells about eight hours after the cells were harvested from their bone marrow. This ensured that results would not be skewed by differences in the quantity or quality of stem cells administered.

Researchers assessed heart improvement six months after stem cell therapy by measuring the percentage of blood that was pumped out of the left ventricle during each contraction (known as the left-ventricular ejection fraction, or LVEF). The study found no significant differences between the change in LVEF readings at the six-month follow-up in either the day three or the day seven stem cell groups compared with placebo groups or with each other. Every group showed about a three percent improvement in LVEF.

Follow this link:
Bone marrow stem cells do not improve short-term recovery after heart attack

CombiCult® Workflow
A overview on how Plasticell (www.plasticell.co.uk) uses combinatorial cell culture (CombiCult®) to discover optimised stem cell differentiation protocols in record time, at a fraction of the cost of the status quo while reducing project return risk. CombiCult® is used by our customers in a range of applications in regenerative medicine, cell therapy and research and development.From:PlasticellLimitedViews:1 0ratingsTime:06:40More inScience Technology

Read more here:
CombiCult® Workflow - Video

blood bank | The Development of Umbilical Cord Blood Stem Cell Therapy
http://www.cordbloodrecommendation.com Umbilical cord blood is stored immediately after delivery, when the cord is cut. Diseases that are genetically based would most likely be an allogenic transplant. Human umbilical cord blood cells are very rich in stem cells and progenitor cells which make them the perfect place to take cells from and then store them in a cord blood bank or a stem cells bank. Scientists have found that umbilical blood can actually help to treat many types of medical issues. To make a long story short, the Adult Stem Cells did the trick. This would be a significant event, which would save thousands of lives of those waiting for an organ. Why would someone opt for cord blood preservation? Well, research is continually being conducted and cells extracted from this blood has already been used to treat and cure injuries and diseases. Cord Blood Banking facilities are places where you can bank your child #39;s cord blood and use it later on in life to cure life-threatening diseases. The National Cord Blood Program staff at the New York Blood Center performs cord blood collection from the expelled placenta. Because of this amazing capacity of blood cells, they have been, still are and will continue to be used more and more to save lives and cure a number of diseases. ""Umbilical cord blood contains blood-forming cells that can be used to treat life-threatening diseases and conditions. Stem cells, researchers discovered, could cure many diseases such as leukemia and ...From:hotelesenMelgarViews:0 0ratingsTime:01:18More inScience Technology

Continued here:
blood bank | The Development of Umbilical Cord Blood Stem Cell Therapy - Video

Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Stem cells are cells which have the potential to develop into virtually any cells of the body. The characteristics of stem cells render them great possibility in treating illness as well as health rejuvenation. Stem cells can repair and renew damaged cells as well as replace the dead ones so that a damaged organ or tissue can be healed to its healthy state. Visit Stem Cell Malaysia at http:/stemcellmalaysia.com/ for more information on stem cells and stem cell therapy.From:stemcells2012Views:1 1ratingsTime:06:33More inHowto Style

Read more here:
Stem Cells | Stem Cell Malaysia - Video

25 Multiple Sclerosis Plr Articles
ll4.me 25 Multiple Sclerosis Plr Articles 25 Multiple Sclerosis Articles - Private Label Rights Article Topics:- Treatment For Multiple Sclerosis With No Side Effects Types Of Multiple Sclerosis What Multiple Sclerotic People Should Avoid during Christmas How To Diagnose Multiple Sclerosis How To Know If It Is A Multiple Sclerosis Relapse How To Treat Multiple Sclerosis Is Cannabis Use Beneficial For Multiple Sclerosis Lifesaving Drug For Multiple Sclerosis More Information On Multiple Sclerosis Multiple Sclerosis Association Of America All About Multiple Sclerosis Causes Of Multiple Sclerosis Childbirth May Slow Multiple Sclerosis Common Human Bacteria Triggers Multiple Sclerosis Good News On Pregnancy And Multiple Sclerosis How Is Multiple Sclerosis Classified The Clinical Part Of Multiple Sclerosis The History Of Multiple Sclerosis The Kurtzke Expanded Disability Status Scale And Multiple Sclerosis Multiple Sclerosis Differential Diagnoses Not Everyone With Multiple Sclerosis Is On Treatment Pathophysiology Of Multiple Sclerosis Stem Cell Therapy Reverses Multiple Sclerosis Symptoms Of Multiple Sclerosis Teenage Obesity and Multiple Sclerosis Use the content on : Blogs/Content Pages Report Social Sites ecourses Convert to Audios ebook Bundle and Sell as Products Personal Education, Tips Training Whatever you might imagine... RIGHTS:- [YES] Can Be Sold [YES] Can Be Packaged [YES] Can Be Offered As a Bonus [YES] Can Be Added As Web Content [YES] Can Be Used For Product ...From:rebeccahenson9854Views:0 0ratingsTime:00:14More inPeople Blogs

Read the original here:
25 Multiple Sclerosis Plr Articles - Video

Stem Cell Research and TNG
How close is Science to providing visors for the blind? Or what about curing blindness? Have you watched the episode "The Masterpiece Society" from season 5 of TNG? Cause I have a couple of philosophical things to say about that! An article about STEM CELL therapy in regards to vision impairment: abcnews.go.com Interview with TrekMate: http://www.trekmate.org.uk ***I feel like the Star Trek community is a lot bigger then what YouTube has to offer, so I #39;ve started uploading my own videos. A lot of you will find this painfully dorky -and it is- which is why constructive criticism is welcomed. For anyone who does like my posts, thank you! It would be nice to gather a little Trekkie community :)***From:ThatTrekkieGirlViews:6 1ratingsTime:06:51More inPeople Blogs

See the article here:
Stem Cell Research and TNG - Video

Thelma before Stem Cell Therapy
From:krazykp12Views:2 0ratingsTime:01:33More inPeople Blogs

Read this article:
Thelma before Stem Cell Therapy - Video

NEW YORK (AP) Shares of biotechnology company Pluristem Therapeutics Inc. bounced back Friday after the company responded to a report that a patient treated with its PLX stem cell therapy had died.

THE SPARK: Bloomberg BusinessWeek reported Thursday that Pluristem did not disclose the death of a young patient who had been treated with its placental cell therapy before a $32 million public stock sale in September. Shares of Pluristem fell 23 percent Thursday.

The Israeli company said Thursday evening that parts of the article were inaccurate or misleading. It said the patient, a Romanian girl whose name has not been disclosed, was "in imminent danger of death" at the time she was treated with the stem cells. She was not part of an organized clinical trial and was treated on a compassionate basis because no therapy options remained.

Pluristem said the patient lived for six months after her treatment. She returned to Romania four months before she died and the company was not monitoring her health. Pluristem said it was not aware of her death at the time it sold the additional stock. Bloomberg said the patient died Sept. 12, the day the stock sale was announced. The sale closed a week later.

"The formal report relating to the death clearly stated that there was no connection between the PLX cell treatment and the death of the patient," Pluristem said in a press release.

THE BIG PICTURE: Pluristem said that three patients have been treated with PLX on a compassionate basis including the Romanian girl and two have died. The company said it believes the patients lived longer than expected following treatment, which demonstrates that PLX therapy can be effective. The company is studying the stem cells as a treatment for peripheral artery disease, nerve pain, and other conditions.

THE STOCK: Shares of Pluristem rose 39 cents, or 13.7 percent, to $3.24 on Friday. The stock reached an annual high of $5 per share in August, and including Friday's gains, the shares are down 29 percent since the company announced the stock offering.

Go here to see the original:
Pluristem shares bounce back after Thursday plunge

Published on 10 November 2012 Hits: 58 Written by Jovee Marie N. Dela Cruz

The Department of Health (DOH) on Friday said that it has become necessary to issue regulations for stem cell therapy in the country. Health Secretary Enrique Ona said that guidelines for clinics offering stem cell therapy will be released immediately by the DOH and the Food and Drug Administration.

We will issue guidelines because here in the country we dont know where the stem cell offered by clinics come from, he said.

According to the DOH, stem cell therapy belongs to the category of advanced cell therapy, which includes biologics and blood. Many countries apply a risk-based approach to assess the quality, efficacy and safety of advanced cell therapy.

In many countries, stem cell is considered an investigational intervention, Ona said.

The DOH said that stem cell research employs both autologous (from same person) or allogenic (from another organism like an animal or another human cell or tissue sample) method.

Ona said that because there are many steps in the preparation of this lab and invasive procedure, there is a need to have a regulatory framework to protect Filipino citizens.

Read more:
DOH to regulate stem cell therapy in PH

PRP Vs Stem Cell Therapy
PRP Therapy Vs Stem Cell TherapyFrom:MiamiFootSurgeryViews:5 0ratingsTime:01:23More inHowto Style

View original post here:
PRP Vs Stem Cell Therapy - Video